Key result
Aldosterone synthase inhibitors increase overall adverse events ~31% vs. placebo, driven by hyperkalemia.
Why the study?
Although the blood pressure-lowering efficacy of aldosterone synthase inhibitors in uncontrolled or resistant hypertension has been demonstrated, their safety profile across randomized trials remained incompletely characterized using absolute risk metrics.
Do aldosterone synthase inhibitors increase the risk of adverse safety outcomes compared to placebo in adults with uncontrolled or resistant hypertension?
Meta-Analysis (n=2,062)
Do aldosterone synthase inhibitors increase the risk of adverse safety outcomes compared to placebo in adults with uncontrolled or resistant hypertension?
While aldosterone synthase inhibitors do not significantly increase serious adverse events in resistant hypertension, they substantially increase the risk of hyperkalemia (NNH 25), hyponatremia (NNH 50), hypotension (NNH 100), and eGFR decline, necessitating close electrolyte and renal monitoring.
Answers are grounded in this paper and cite their sources.
Requires electrolyte monitoring with aldosterone synthase inhibitors; extends safety data from efficacy trials in resistant hypertension.
Introduction: Aldosterone synthase inhibitors (ASIs) represent a novel class of antihypertensive agents targeting aldosterone synthesis in patients with uncontrolled or resistant hypertension. Though their blood pressure-lowering efficacy has been demonstrated, their safety profile across randomized trials remains incompletely characterized using absolute risk metrics. Objective: To evaluate the safety profile of ASIs in uncontrolled and resistant hypertension by quantifying absolute risks. Methods: We conducted an extensive database review for randomized controlled trials (RCTs) evaluating ASIs in adults with uncontrolled or resistant hypertension vs. placebo. The primary objective was to assess safety outcomes, including overall adverse events, serious adverse events (SAE), treatment discontinuation, hyperkalemia, hyponatremia, hypotension, and decline in estimated glomerular filtration rate (eGFR) >25%. Pooled odds ratios (OR) with 95% confidence intervals (CIs) were calculated using random-effects models. Risk differences (RDs) were used to estimate absolute risk changes, from which numbers needed to harm (NNH) were derived. Statistical heterogeneity was assessed using the I 2 statistic. Results: We included 7 RCTs involving 2,062 participants (ASI n=1,161; placebo n=901). ASIs had an increased risk of overall adverse events (OR 1.31, p=0.04), treatment discontinuation (OR 2.94, p=0.03), hyperkalemia (OR 4.93, p=0.0006), hypotension (OR 3.32, p=0.008), hyponatremia (OR 2.01, p=0.02), and eGFR decline (OR 3.48, p=0.02). SAEs were not significantly increased (OR 1.32, p=0.33). Hyperkalemia risk was increased with both Baxdrostat and Lorundrostat, with no significant subgroup differences (p=0.81). Hyperkalemia was more frequent at 12 weeks than at 6-8 weeks (OR 11.50 vs. 2.38; p = 0.08). No significant subgroup differences by drug or treatment duration were observed for serious adverse events, hypotension, or hyponatremia (all interaction p > 0.05). Absolute risk increases corresponded to an NNH of 25 for hyperkalemia, 50 for hyponatremia, and 100 for hypotension. Conclusion: ASIs are associated with a significant increase in several adverse events, though serious adverse events remain unchanged. Hyperkalemia, hyponatremia, and hypotension were clinically relevant adverse events frequently requiring dose adjustment or medical intervention. Absolute risk estimates indicate the need for careful monitoring when using ASIs in resistant hypertension.
No takes yet. Share an insight, caveat, or question.
Meda et al. (2026) conducted a meta-analysis in Uncontrolled or resistant hypertension (n=2,062). Aldosterone synthase inhibitors (including baxdrostat and lorundrostat) vs. Placebo was evaluated on Overall adverse events (alongside specific safety outcomes including serious adverse events, treatment discontinuation, hyperkalemia, hyponatremia, hypotension, and decline in eGFR >25%) (OR 1.31, p=0.04). Aldosterone synthase inhibitors increased overall adverse events and hyperkalemia vs placebo without increasing serious adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: